Features | Partner Sites | Information | LinkXpress
Sign In
Advantech Europe
Ampronix
Schiller

Blood Test Measures Hodgkin’s Chemotherapy Success

By HospiMedica International staff writers
Posted on 06 Mar 2013
A cheap and easy to use diagnostic test helps determine the success of chemotherapy in patients enduring Hodgkin’s lymphoma (HL).

Researchers at the Queensland Institute of Medical Research (QIMR; Brisbane, Australia), the University of Melbourne (Australia), and other institutions prospectively measured serum CD163 (sCD163) and the Hodgkin-Reed-Sternberg (HRS)-specific serum protein sTARC in 221 samples taken from 47 patients with HL, and 21 healthy participants. Blood was drawn at five fixed time-points prior, during, and after first-line therapy. The results were compared with radiological assessment and plasma Epstein-Barr virus DNA (EBV-DNA). The researchers also examined potential sources of circulating CD163, as well as immunosuppressive properties of CD163.

The results showed that prior to therapy, both sCD163 and sTARC were markedly elevated compared with healthy and complete remission samples; sCD163 better reflected tumor burden during therapy, and sTARC presenting greater value upon completion of therapy. Additionally, sCD163 correlated with plasma EBV-DNA, and was associated with B symptoms, stage, and lymphopenia. The researchers found that the combination of both proteins was more informative as a disease response biomarker than either marker alone, in early and advanced disease during first-line therapy for classical HL. The study was published in the February 2013 issue of Clinical Cancer Research.

“This has the potential to be a huge aid for doctors in their decision making and a faster and less invasive process for the patients. Up until now, clinicians have relied on scans to help them judge how well people are responding to chemotherapy,” said lead author Professor Maher Gandhi, PhD, of the QIMR Clinical Immunohaematology Laboratory. “This discovery means we can work towards using simple blood tests to provide quicker, cheaper, and more regular monitoring of how a person is responding to treatment.”

Response biomarkers for classical HL might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. While HRS cells are sparse within the diseased node, benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. It is known that CD163(+) cells within the malignant node may be prognostic, but until now there has been no data on serum CD163.

Related Links:

Queensland Institute of Medical Research
University of Melbourne



Cincinnati Sub-Zero
Anetic Aid
ECR

Channels

Women's Health

view channel
Image: The Koala Toco disposable tocodynamometer (Photo courtesy of Clinical Innovations).

Disposable Dynamometer Measures Uterine Contractions

An innovative tocodynamometer utilizes air-charged technology to accurately measure uterine contractions. The Koala Toco is a single-use disposable tocodynamometer with no electronic components, making... Read more

Health IT

view channel

Doctors Claim EHRs Do Not Save Money or Time

A recent survey claims that 75% of physicians in the United States who use electronic health records (EHRs) say they are not cost- or time-effective, but do have value in terms of providing data. The Deloitte (New York, NY, USA) 2014 Survey examined US physicians’ current use and overall views of mobile health (mHealth)... Read more

Hospital News

view channel
Image: Aerial view of Fiona Stanley Hospital (Photo courtesy of the Government of Western Australia).

Fiona Stanley Hospital Opens in Southern Perth

Western Australia (WA) has officially opened its newest health care facility, the state's first new-build tertiary hospital project in more than 50 years. Fiona Stanley Hospital (FSH; Murdoch, Australia)... Read more

Business

view channel

Steris to Buy British Sterilization Services Provider Synergy Health

Steris (Mentor, OH, USA) will also shift is headquarters to a new, UK-based company, thus joining a growing list of companies that are trying to cut taxes by shifting their corporate domicile from the United States. Steris said the combined company, to be called Steris, will be incorporated in the United Kingdom, but... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.